Experts Report the Latest Updates in Pulmonary Disease
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD
New Research on Therapies for Patients with Pulmonary Fibrosis
Spring 2019 — What are the Most Exciting Things Happening in Pulmonary Disease?
New Tools to Improve the Diagnosis of IPF vs Other ILDs
Biomarkers in IPF and Other ILDs
Connective Tissue Disease-Related ILD is Now in the Limelight
Patient-Centered Outcomes for Patients with IPF: Activity Monitoring
The Impact of Anticoagulation Use on IPF Patient Outcomes: A Warning About Warfarin
Which Patients with IPF Should be on Antifibrotics? The Value of Shared Decision Making
Dyspnea Assessment in Patients with IPF
